skip to content

Market News

Consort announces master development agreement

14 October 2016 07:32

Consort Medical said that Bespak has entered into a master development agreement including key commercial supply terms with a leading global biopharmaceutical company.

The agreement is focused on Bespak's novel Vapoursoft driven auto-injector technology, Syrina.

Under the agreement, Bespak will develop a Syrina embodiment of a single product through to commercialisation.

The framework of the agreement also allows for inclusion of additional development programmes for other products.

In the event that the Company elects to commercialise the developed device, the agreement provides that the parties will enter into a full commercial supply agreement.

Syrina is one of a range of novel technologies developed at Bespak's Cambridge, UK based Innovation Centre.

Through the use of a liquid gas propellant, rather than a spring to drive the delivery of the drug, Syrina facilitates delivery of a broader range of drug formulations and volumes, whilst also reducing or eliminating potential for glass syringe breakage.

Story provided by StockMarketWire.com

Related Company: CSRT

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

-

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.